Sunday, September 25, 2022 | Back issues
Courthouse News Service Courthouse News Service

$9 Billion Merger

Directors are selling Juno Therapeutics too cheaply through an unfair process to Celgene, for $87 a share or $9 billion, shareholders claim in a federal class action.

SEATTLE — Directors are selling Juno Therapeutics too cheaply through an unfair process to Celgene, for $87 a share or $9 billion, shareholders claim in a federal class action.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...